Phase Ii Study Of Gedatolisib For Small-Cell Lung Cancer (Sclc) Patients (Pts) With Genetic Alterations In Pi3k/Akt/Mtor Pathway Based On A Large-Scale Nationwide Genomic Screening Network In Japan (Eagle-Pat/Lc-Scrum-Japan).